JP2001524951A - 炎症性腸疾患を治療するための方法および組成物 - Google Patents

炎症性腸疾患を治療するための方法および組成物

Info

Publication number
JP2001524951A
JP2001524951A JP54099898A JP54099898A JP2001524951A JP 2001524951 A JP2001524951 A JP 2001524951A JP 54099898 A JP54099898 A JP 54099898A JP 54099898 A JP54099898 A JP 54099898A JP 2001524951 A JP2001524951 A JP 2001524951A
Authority
JP
Japan
Prior art keywords
mycobacterial
composition
product
treatment
rifabutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP54099898A
Other languages
English (en)
Japanese (ja)
Inventor
トーマス ジュリアス ボロディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Individual filed Critical Individual
Publication of JP2001524951A publication Critical patent/JP2001524951A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP54099898A 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物 Withdrawn JP2001524951A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
AU9785 1997-10-14
AU5940 1997-10-14
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007232402A Division JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物

Publications (1)

Publication Number Publication Date
JP2001524951A true JP2001524951A (ja) 2001-12-04

Family

ID=25645389

Family Applications (3)

Application Number Title Priority Date Filing Date
JP54099898A Withdrawn JP2001524951A (ja) 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物
JP2012062968A Pending JP2012126736A (ja) 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物
JP2012062968A Pending JP2012126736A (ja) 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2013508428A (ja) * 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
KR20140082982A (ko) 2011-09-20 2014-07-03 레드힐 바이오파마 엘티디 자기 면역 질환 치료용 조성물 및 방법

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
EP1150666B1 (en) * 1999-02-12 2009-10-28 Washington University Gm-csf for the treatment of crohn's disease
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
EP1642885B1 (en) * 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of bound immunoregulatory compounds
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
EP2280713A1 (en) * 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
BR112012027520A2 (pt) 2010-04-26 2015-09-15 Salix Pharmaceuticals Ltd formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino
SG191145A1 (en) 2010-12-13 2013-07-31 Borody Thomas J Gastric and colonic formulations and methods for making and using them
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
EP3145510B8 (en) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
CA3187031A1 (en) 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2013508428A (ja) * 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
US9468663B2 (en) 2009-10-26 2016-10-18 Thomas Julius Borody Enteric combination therapy
US10517922B2 (en) 2009-10-26 2019-12-31 Thomas Julius Borody Enteric combination therapy
US11344602B2 (en) 2009-10-26 2022-05-31 Thomas Julius Borody Enteric combination therapy
US11471505B2 (en) 2009-10-26 2022-10-18 Thomas Julius Borody Enteric combination therapy
US11612635B2 (en) 2009-10-26 2023-03-28 Thomas Julius Borody Enteric combination therapy
KR20140082982A (ko) 2011-09-20 2014-07-03 레드힐 바이오파마 엘티디 자기 면역 질환 치료용 조성물 및 방법
JP2014526548A (ja) * 2011-09-20 2014-10-06 レッド ヒル バイオファーマ リミテッド 自己免疫疾患を処置するための組成物および方法
US9901638B2 (en) 2011-09-20 2018-02-27 Redhill Biopharma Ltd. Composition and method for treating an autoimmune disease

Also Published As

Publication number Publication date
ES2303351T3 (es) 2008-08-01
WO1998043667A1 (en) 1998-10-08
ATE389417T1 (de) 2008-04-15
DK0971735T3 (da) 2008-07-07
US6277836B1 (en) 2001-08-21
IL132145A0 (en) 2001-03-19
CA2285923C (en) 2013-03-12
NZ500696A (en) 2002-05-31
NO325947B1 (no) 2008-08-25
SI0971735T1 (sl) 2008-08-31
EP0971735B1 (en) 2008-03-19
CA2285923A1 (en) 1998-10-08
JP2012126736A (ja) 2012-07-05
CY1109783T1 (el) 2013-09-04
NO994778D0 (no) 1999-09-30
AR012304A1 (es) 2000-10-18
DE69839261D1 (de) 2008-04-30
DE69839261T2 (de) 2009-03-26
EP0971735A4 (en) 2004-02-25
IL132145A (en) 2005-11-20
PT971735E (pt) 2008-06-02
EP0971735A1 (en) 2000-01-19
NO994778L (no) 1999-11-30
JP2008024713A (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
US6277836B1 (en) Methods and compositions for treating inflammatory bowel disease
US6551632B2 (en) Methods and compositions for treating inflammatory bowel disease
JP4651816B2 (ja) クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
TWI573590B (zh) 治療自體免疫疾病之組成物及方法
EP4635573A2 (en) Delayed release deferiprone tablets and methods of using the same
KR20150118176A (ko) 헬리코박터 파일로리 치료용 약제학적 조성물
CN111870607A (zh) 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法
AU690661B2 (en) New use of quinoline-3-carboxamide compounds
JP2006502193A5 (enExample)
JP2006502193A (ja) 前立腺疾病を治療するためのヨクイニン油軟カプセル剤
AU750813B2 (en) Methods and compositions for treating inflammatory bowel disease
AU774329B2 (en) Methods and compositions for treating inflammatory bowel disease
WO2005074908A1 (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
JP2024523123A (ja) 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用
JP2024516326A (ja) 去勢抵抗性前立腺がんの治療薬の調製におけるポラプレジンクの使用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070813

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070921

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20071115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080214

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080925